Your session is about to expire
← Back to Search
NG101m Adjuvant Therapy for Glioblastoma
Study Summary
This trial is testing a new drug to see if it helps people with glioblastoma multiforme, a type of brain cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot reduce my steroid medication to a low dose.My main treatment is a combination of chemotherapy and radiation.I have had a peptic ulcer or a hole in my digestive tract.I am not using any alternative therapies.I am 18 years old or older.I am able to care for myself but may not be able to do active work.I have been recently diagnosed with glioblastoma.
- Group 1: NG101m and standard treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the uppermost limit of participants in this clinical experiment?
"At this time, no further enrolment is possible for this medical trial. It was initially made available on the 1st of January 2023 and last updated on April 22nd 2022. Should you be interested in other research initiatives, there are currently 441 studies searching for glioblastoma patients and 207 trials actively recruiting participants for NG101m therapy."
Is this experiment a pioneering effort in its field?
"There are over 900 cities and 36 nations with active clinical trials for NG101m. This substance was initially researched in 2002 by Schering-Plough, which ran a 60 participant Phase 2 drug approval study: since then, 301 investigations have been completed."
Has NG101m been the subject of any other investigations?
"Currently, 207 clinical trials are being conducted with regard to NG101m. Of those studies, 24 have advanced to Phase 3 and the majority occur in Seoul Songpa. However, 4752 medical centres around the world are running research on this drug treatment."
Is participation in this research endeavor still available to patients?
"Unfortunately, no additional patients are being sought for this trial at present. As of April 22nd 2022, the study has not been updated since its initial posting on January 1st 2023. On the bright side, there are a plethora of open trials recruiting participants with glioblastoma (441) and NG101m (207)."
In what conditions is NG101m typically employed?
"NG101m is the typical nitrosourea treatment, however it can also be beneficial for numerous other medical cases such as refractory mycosis fungoides, advanced directives and neuroblastoma that have become resistant to conventional treatments."
Share this study with friends
Copy Link
Messenger